Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148031 · ClinicalTrials.gov registry record · Phase 4
Improving Hepatitis C Treatment in Injection Drug Users
A Phase 4 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 111
- Enrollment target
NCT00148031: Completed Phase 4 study, sponsored by State University of New York - Upstate Medical University.
NCT00148031 is a Phase 4 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 111 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00148031, a Phase 4 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 111 participants
- Enrollment target
Study Summary
The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increase access by integrating HCV medical care into a substance abuse treatment program.
Interventions
- DRUG Pegylated Interferon and Ribavirin
- BEHAVIORAL Psychosocial
- BEHAVIORAL On-site (MMT Clinic) HCV evaluation and treatment
- BEHAVIORAL Off-site HCV evaluation and treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
What the finished NCT00148031 record still lists
NCT00148031 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 4 interventions - of which Pegylated Interferon and Ribavirin is the first listed.
NCT00148031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00148031 about?
NCT00148031 is a clinical study titled "Improving Hepatitis C Treatment in Injection Drug Users". The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increas...
What is the current status of trial NCT00148031?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 111 participants. The study started on 2003-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00148031?
The interventions under investigation include: Pegylated Interferon and Ribavirin (DRUG), Psychosocial (BEHAVIORAL), On-site (MMT Clinic) HCV evaluation and treatment (BEHAVIORAL), Off-site HCV evaluation and treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00148031?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00148031's enrollment target sits among peer trials
111 726th of 2000 higher than 1,274 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia